We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A UK and Europe-wide review of available efficacy and safety data confirmed that reboxetine has benefit over placebo in its authorised indication.
Risk of serious haemorrhage—clarified contraindications apply to all 3 medicines.
A recent Europe-wide review of the safety information for alli has led to a number of updates, which bring the product information in line with that for Xenical.
Indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use.
Saquinavir at a reduced dose for the first week of treatment
Government response to the report by the Advisory Council on the Misuse of Drugs on acyl piperazine opioids, including 2-methyl-AP-237.
This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.
Domperidone is no longer licensed for use in children younger than 12 years or those weighing less than 35 kg. Results from a placebo-controlled study in children younger than 12 years with acute gastroenteritis did not show…
Provide clear information to patients and caregivers about how to minimise the risk of accidental exposure and the importance of appropriate disposal of patches. We continue to receive reports of unintentional opioid toxicit…
Detailed recommendations for dose restrictions when used with some other drugs as interactions may increase the risk of adverse effects, or reduce the effectiveness of statin treatment.
A change to the Misuse of Drugs Act 1971.
Public Health England (PHE) has issued a warning of a sharp rise in the number of overdoses linked to people using drugs in several areas across England.
Patient reminder cards about the risk of osteonecrosis of the jaw are being introduced; denosumab 120 mg is now contraindicated in patients with unhealed lesions from dental or oral surgery.
There is a risk of harmful drug interactions with the ritonavir component of the COVID-19 treatment Paxlovid▼ due to its inhibition of the enzyme CYP3A, which metabolises many commonly used drugs. Prescribers should obtain a…
In 2008 MHRA commissioned Ipsos MORI to research the public’s perception of herbal medicines, the findings may help doctors and pharmacists when considering how to advise patients.
This project reviewed the factors that influence variability and uncertainty in measurements of concentrations of methane in groundwater.
The Advisory Council on the Misuse of Drugs has undertaken a review of the evidence on the use and harms of diphenidine and other related substances.
Using inverse dispersion modelling to quantify methane emissions from industrial sites.
Decisions made by MHRA following an investigation into complaints about advertising for licensed medicines.
ACMD work programme 2024 letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).